Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux pharmacokinetics in morbidly obese patients after bariatric surgery
2009-016417-15Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Nov 2009
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fondaparinux in class III obesity and venous thromboembolism (VTE), sponsored by CHU Saint-Etienne. Primary endpoint: Fondaparinux plasma concentration via anti-Xa activity. Started Nov 2009; status: completed.
02
Drugs
fondaparinux
03
Conditions
class III obesityvenous thromboembolism (VTE)
Beyond the preview
Go deeper on 2009-016417-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016417-15.